Your Clotting Risk Is Written in Your DNA. Here's What It Says.

Factor V is one of your blood’s main clotting proteins. Your liver makes it constantly, and when you bleed, Factor V works with other proteins to form a clot and stop the bleeding. It’s essential. Once the bleeding stops, another protein called activated protein C is supposed to deactivate Factor V and prevent the clot from getting too big. That feedback loop keeps clotting balanced.

The Factor V Leiden variant, also called R506Q, makes Factor V resistant to activated protein C. Roughly 5% of people with European ancestry carry this variant, and it increases venous thromboembolism risk by 4 to 8 times. Your clots don’t stop forming as efficiently. They linger. They grow.

For women on oral contraceptives, the risk spikes dramatically to roughly 80 times normal. For anyone facing surgery, long travel, or pregnancy, this variant demands attention. You may never develop a clot, but the risk is there, written into every cell.

Prothrombin (Factor II) is the first domino in the clotting cascade. When you bleed, prothrombin converts to thrombin, which then triggers the rest of the cascade and forms a clot. Your liver produces prothrombin continuously, and its levels stay balanced in most people.

The F2 G20210A variant causes your liver to produce more prothrombin than normal. About 2 to 3% of people with European ancestry carry this variant, and it roughly doubles to triples your clotting risk. The effect is modest compared to Factor V Leiden alone, but it’s dangerous in combination. If you carry both F2 and F5 variants, your thrombosis risk compounds significantly.

You may never feel this happening. Prothrombin levels don’t cause pain or obvious symptoms. The risk reveals itself only through clots, sometimes years later. People who’ve had unexplained thrombosis often discover the F2 variant only after testing.

MTHFR converts folate into methylfolate, the active form your cells use to manage homocysteine. Homocysteine is an amino acid your body produces constantly. Keep it low, and your arteries stay healthy. Let it accumulate, and it damages your blood vessel walls, promotes clotting, and increases heart attack and stroke risk independent of cholesterol or blood pressure.

The MTHFR C677T variant reduces enzyme efficiency by 40 to 70%. Roughly 40% of people with European ancestry carry at least one copy, and the effects range from mild to significant depending on other genetic factors and nutrition. Your cells can’t convert folate fast enough, so homocysteine builds up silently. You feel nothing. Your standard cholesterol panel shows nothing. But your arteries are taking damage.

Years of elevated homocysteine quietly increases your clotting tendency, hardens your arteries, and raises your heart attack and stroke risk. Combined with F5 or F2 variants, MTHFR deficiency amplifies clotting risk. Combined with smoking, high blood pressure, or poor diet, the effect compounds.

Once a clot forms and does its job, your body needs to dissolve it. Plasminogen activators break down the fibrin mesh that holds clots together, and PAI1 (plasminogen activator inhibitor-1) regulates how fast that happens. PAI1 acts as a brake on clot breakdown. A little brake is good. Too much brake is dangerous.

The PAI1 4G/5G polymorphism shifts the balance. People with the 4G/4G genotype produce more PAI1 than others. About 25% of the population carries 4G/4G, and these individuals have slower clot breakdown and roughly 1.5 to 2 times higher thrombosis risk, plus higher heart attack risk even in the absence of clotting disorders. Your body is slower to dissolve clots once they form. They linger longer than they should.

PAI1 4G/4G combines dangerously with F5 Leiden or F2 variants. The clot forms more easily and dissolves more slowly. For people with recurrent clots, recurrent heart attacks, or unexplained thrombosis, PAI1 4G/4G is often the missing piece.

Nitric oxide is one of your blood vessels’ most important signaling molecules. When your arteries are healthy, they produce nitric oxide, which tells the muscle surrounding the arteries to relax and dilate. Relaxed arteries have lower pressure, better blood flow, and less turbulence that might trigger clotting. Nitric oxide also inhibits platelet activation directly, making clots less likely to form.

NOS3 (endothelial nitric oxide synthase) is the enzyme that produces nitric oxide in your blood vessels. The Glu298Asp variant (rs1799983) reduces nitric oxide production. About 30 to 40% of the population carries this variant, and it impairs blood vessel dilation, raises blood pressure, and increases atherosclerosis and thrombosis risk. Your arteries constrict more, blood pressure climbs, and your blood’s tendency to clot increases.

NOS3 variants don’t cause sudden events. They shift your baseline. You might notice higher blood pressure, easier fatigue with exertion, or a vague sense that your circulation isn’t optimal. Years later, clots form in narrowed vessels, or plaque ruptures because the arteries can’t relax properly. Combined with smoking, high blood pressure, or other clotting variants, NOS3 Glu298Asp accelerates cardiovascular disease.

Vitamin K is the cofactor your liver needs to produce clotting factors including Factors II, VII, IX, and X. But vitamin K is used up in that process, so your liver needs to recycle it. VKORC1 (vitamin K epoxide reductase complex subunit 1) does that recycling. Without efficient recycling, your liver can’t produce enough clotting factors, and your blood doesn’t clot properly.

VKORC1 variants affect how efficiently you recycle vitamin K. Some variants reduce VKORC1 function, meaning you require more dietary vitamin K to maintain adequate clotting factors. More importantly, VKORC1 variants dramatically affect how you respond to warfarin (a vitamin K antagonist used to prevent clots), which is why pharmacogenomic testing always includes VKORC1. People with reduced-function variants need lower warfarin doses to achieve the same anticoagulation effect, while those with higher-function variants need higher doses.

If you’re managing a clotting disorder with warfarin or another anticoagulant, VKORC1 testing determines your optimal dose and monitoring strategy. If you’re not on anticoagulation but carry a VKORC1 variant, you may need more dietary vitamin K or be more sensitive to supplements that interfere with vitamin K, like high-dose vitamin E.